See the DrugPatentWatch profile for Plegridy
Plegridy, an interferon beta-1a medication used to treat relapsing forms of multiple sclerosis (MS), received approval from the U.S. Food and Drug Administration (FDA) on August 20, 2014 [1]. It was developed by Biogen Idec [1].
How does Plegridy work for MS?
Plegridy is a modified version of interferon beta-1a, a naturally occurring protein that plays a role in the immune system. In multiple sclerosis, the immune system mistakenly attacks the protective sheath around nerve fibers in the brain and spinal cord. Interferon beta-1a is believed to help reduce inflammation and modify the immune system's activity, potentially slowing the progression of the disease and reducing the frequency of relapses [1].
What are the different formulations of Plegridy?
Plegridy is available in two formulations: a pre-filled pen and a pre-filled syringe, both designed for subcutaneous injection every two weeks [1].
When can biosimilars of Plegridy be expected?
The patent landscape for Plegridy and its related technologies is complex and can influence the timeline for biosimilar entry. Information regarding specific patent expiries and potential biosimilar competition can be found on resources like DrugPatentWatch.com [2].
What clinical data supported Plegridy's approval?
The FDA's approval of Plegridy was based on data from two pivotal Phase 3 clinical trials: the ADVANCE study and the double-blind, placebo-controlled trial that supported the PLEO-AF (African American) study [1]. These studies demonstrated that Plegridy significantly reduced the annualized relapse rate in patients with relapsing MS compared to placebo [1].
What are the common side effects reported for Plegridy?
Common side effects associated with Plegridy use include injection site reactions, flu-like symptoms, headache, and fatigue [1]. Patients may also experience muscle aches and abdominal pain. As with other interferons, there is a risk of liver enzyme elevations and a potential for decreased white blood cell counts [1].
How does Plegridy compare to other MS treatments?
Plegridy belongs to the class of interferon beta medications, which have been a cornerstone of MS treatment for many years. While interferons like Plegridy offer a benefit in managing relapsing forms of MS, newer disease-modifying therapies with different mechanisms of action, such as sphingosine-1-phosphate (S1P) receptor modulators and monoclonal antibodies, have also emerged and are used to treat MS [3]. The choice of treatment depends on individual patient factors, disease activity, and physician recommendation.
What is the regulatory status of Plegridy in other regions?
Following its U.S. approval, Plegridy also received approval from the European Medicines Agency (EMA) in November 2014 [4].
Where can I find more information about Plegridy patents?
Detailed information on Plegridy's patent status, including expiration dates and any ongoing patent litigation, can be accessed through specialized patent tracking websites such as DrugPatentWatch.com [2].
Who manufactures Plegridy?
Plegridy is manufactured by Biogen [1].
Sources:
1. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/plegridy-fda-drug-safety-communication
2. https://drugpatentwatch.com/
3. https://www.nationalmssociety.org/Treating-MS/Medications
4. https://www.biogen.com/en_US/news-releases/plegridy-receives-european-commission-approval-for-treatment-of-relapsing-remitting-multiple-sclerosis.html